Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed patients with gastrointestinal cancers, including pancreas, liver, gastric cancer, gastrointestinal stromal tumors, and metastatic cancers undergoing surgical resection as standard of care treatment.
At least 18 years of age.
For the first cohort of patients enrolled, must have an ECG with no prolonged intervals.
Able to understand and willing to sign a written informed consent document.
You may not be if
Contraindications for surgery.
Receiving any investigational agents.
History of allergic reactions attributed to ICG or other agents used in the study, include known iodide or seafood allergy. We do not expect many of these adverse reactions with LS301 because it is not radioactive and does not possess iodinated counterions.
Presence of underlying lung disease.
Pregnant. Female patients of childbearing potential must have a negative serum or urine pregnancy test no more than 7 days before start of participation.
Breastfeeding. Patients who are breastfeeding are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LS301.
